Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company's product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics Inc. is based in Bedford, Massachusetts.
| Revenue (Most Recent Fiscal Year) | $36.56M |
| Net Income (Most Recent Fiscal Year) | $-88.98M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | 12.32 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.78 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.52 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 27.00% |
| Net Margin (Trailing 12 Months) | 26.33% |
| Return on Equity (Trailing 12 Months) | 19.08% |
| Return on Assets (Trailing 12 Months) | 15.72% |
| Current Ratio (Most Recent Fiscal Quarter) | 8.41 |
| Quick Ratio (Most Recent Fiscal Quarter) | 8.41 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.41 |
| Earnings per Share (Most Recent Fiscal Quarter) | $1.90 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.65 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.79 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 54.60M |
| Free Float | 48.43M |
| Market Capitalization | $531.23M |
| Average Volume (Last 20 Days) | 0.68M |
| Beta (Past 60 Months) | 1.20 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 11.30% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |